CCT020312 manufacturers
- CCT020312
-
- $56.00 / 1mg
-
2026-04-10
- CAS:324759-76-4
- Min. Order:
- Purity: 99.12%
- Supply Ability: 10g
- CCT020312
-
- $56.00 / 1mg
-
2026-04-10
- CAS:324759-76-4
- Min. Order:
- Purity: 99.12%
- Supply Ability: 10g
|
| | CCT020312 Basic information |
| Product Name: | CCT020312 | | Synonyms: | CCT020312;2(1H)-Quinolinone, 6-bromo-3-[5-(4-bromophenyl)-1-[3-(diethylamino)-1-oxopropyl]-4,5-dihydro-1H-pyrazol-3-yl]-4-phenyl-;CCT-020312,CCT020312;EIF2AK3 Activator, CCT020312 | | CAS: | 324759-76-4 | | MF: | C31H30Br2N4O2 | | MW: | 650.4 | | EINECS: | | | Product Categories: | | | Mol File: | 324759-76-4.mol |  |
| | CCT020312 Chemical Properties |
| density | 1.48±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: soluble | | form | A solid | | pka | 9.43±0.70(Predicted) | | color | Light yellow to yellow | | SMILES | O=C1C(C2=NN(C(CCN(CC)CC)=O)C(C3=CC=C(Br)C=C3)C2)=C(C4=CC=CC=C4)C5=CC(Br)=CC=C5N1 |
| WGK Germany | WGK 2 | | Storage Class | 11 - Combustible Solids |
| | CCT020312 Usage And Synthesis |
| Uses | CCT020312 is a selective EIF2AK3/PERK activator. CCT020312 elicits EIF2A phosphorylation in cells. | | Biological Activity | CCT020312 is a selective activator of EIF2AK3/PERK. It induces phosphorylation of EIF2A in cells. | | in vitro | CCT020312 treatment effectively inhibits cell proliferation (as measured at 96 hours) even if treatment is for 2 hours only with subsequent compound washout, indicating that CCT020312 is capable of eliciting durable rather than transient cytostasis. | | in vivo | Treatment of 15-week-old wildtype mice with the PERK activator CCT020312 (1-5 mg/kg; i.p.; once daily for 3 days) leads to increased levels of phosphorylated PERK and NRF2 in brain homogenates[2].
P301S transgenic mice treated with CCT020312 (2 mg/kg; i.p.; once daily for 6 weeks) performes significantly better in Morris water maze[2]. | Animal Model: | 9-week-old P301S tau transgenic mice[2] | | Dosage: | 2 mg/kg | | Administration: | Intraperitoneal injection; once daily for 6 weeks | | Result: | P301S transgenic mice treated with CCT020312 performed significantly better in Morris water maze.
|
| | target | | | References | [1] Stockwell SR, et al.Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling. PLoS One. 2012;7(1):e28568. DOI:10.1371/journal.pone.0028568
[2] Bruch J, et al. PERK activation mitigates tau pathology in vitro and in vivo. EMBO Mol Med. 2017 Mar;9(3):371-384. DOI:10.15252/emmm.201606664 |
| | CCT020312 Preparation Products And Raw materials |
|